Drug Detail

Information about BEZ235

Generic Name
Brand Name (US)
Drug Type
Approval Status
Phase 1
Overall Strategy
Oncogenic Signal Path Based
Block KIT Signal Path
Drug Category
mTOR inhibitor PI3K inhibitor

BEZ235: This oral drug from Novartis targets Class I PI3Ks and mTOR. It is one of two PI3K inhibitors from Novartis currently in phase I. This is a combined Phase I/I trial, with an accrual goal of 80 patients. The trial design will admit solid tumors in Phase I. However, Phase II is limited to breast cancer patients. It is currently available at The Nevada Cancer Institute, Las Vegas, Nev. and at Sarah Cannon Research Institute in Nashville, Tenn. NCT00620594
PI3K proteins have been identified in crucial signaling paths of multiple cancers. They can become over-active via a variety of mechanisms including upstream signaling. PI3Ks have recently been identified as active downstream signal points in the c-KIT pathway in GIST. A number of PI3K inhibitors have now entered phase I clinical trials.